Baseline characteristics of the both cohorts
| . | Cohort 1 (n = 179) . | Cohort 2 (n = 342) . |
|---|---|---|
| Age, median (range), y | 62 (35-89) | 64 (32-88) |
| Male, n (%) | 120 (67) | 227 (66) |
| BMPCs, median (IQR), % | 10 (5-16) | 10 (5-17) |
| dFLC, median (IQR), mg/dL | 34.6 (14.4-79.4) | 25.2 (7.9-66.2) |
| iFLC, median (IQR), mg/dL | 34.3 (15.8-80.5) | 26.7 (9.9-67.3) |
| Urine 24-h protein, median (range), g | 0.2 (0-8.3) | 0.8 (0.1-22.8) |
| Creatinine, median (IQR), mg/dL | 1.2 (1-1.5) | 1.02 (0.8-1.5) |
| Creatinine >2 mg/dL, n (%) | 14 (8) | 41 (12) |
| Alkaline phosphatase, median (IQR), U/L | 99 (79-148) | 85 (65-125) |
| NT-proBNP, median (range), pg/mL | 4554 (2 323-10 321) | 1878 (314-5906) |
| Troponin T, median (range), ng/mL | 0.06 (0.03-0.12) | 0.02 (0.01-0.06) |
| Echocardiographic features, n (%) | ||
| LVEF <55% | 89 (51) | 74 (22) |
| LVIS >14 mm | 105 (61) | 121 (35) |
| LV strain rate >−19% | 94 (95) | 259 (76) |
| . | Cohort 1 (n = 179) . | Cohort 2 (n = 342) . |
|---|---|---|
| Age, median (range), y | 62 (35-89) | 64 (32-88) |
| Male, n (%) | 120 (67) | 227 (66) |
| BMPCs, median (IQR), % | 10 (5-16) | 10 (5-17) |
| dFLC, median (IQR), mg/dL | 34.6 (14.4-79.4) | 25.2 (7.9-66.2) |
| iFLC, median (IQR), mg/dL | 34.3 (15.8-80.5) | 26.7 (9.9-67.3) |
| Urine 24-h protein, median (range), g | 0.2 (0-8.3) | 0.8 (0.1-22.8) |
| Creatinine, median (IQR), mg/dL | 1.2 (1-1.5) | 1.02 (0.8-1.5) |
| Creatinine >2 mg/dL, n (%) | 14 (8) | 41 (12) |
| Alkaline phosphatase, median (IQR), U/L | 99 (79-148) | 85 (65-125) |
| NT-proBNP, median (range), pg/mL | 4554 (2 323-10 321) | 1878 (314-5906) |
| Troponin T, median (range), ng/mL | 0.06 (0.03-0.12) | 0.02 (0.01-0.06) |
| Echocardiographic features, n (%) | ||
| LVEF <55% | 89 (51) | 74 (22) |
| LVIS >14 mm | 105 (61) | 121 (35) |
| LV strain rate >−19% | 94 (95) | 259 (76) |
BMPC, bone marrow plasma cell; dFLC, difference between involved and uninvolved free light chains; iFLC, involved free light chain; IQR, interquartile ratio.